계명대학교 의학도서관 Repository

A Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of DA-9701 (Motilitone) in Patients With Constipation-type Irritable Bowel Syndrome and Functional Dyspepsia Overlap: A Pilot Study

Metadata Downloads
Author(s)
Ju Yup LeeNayoung KimHyuk YoonCheol Min ShinYoung Soo ParkDong Ho Lee
Keimyung Author(s)
Lee, Ju Yup
Department
Dept. of Internal Medicine (내과학)
Journal Title
J Neurogastroenterol Motil
Issued Date
2022
Volume
28
Issue
2
Keyword
DA-9701ConstipationDyspepsiaIrritable bowel syndrome
Abstract
Background/Aims:
To assess the effects and safety of DA-9701 (Motilitone) in patients with constipation-type irritable bowel syndrome (IBS-C) which frequently accompany functional dyspepsia (FD).

Methods:
FD and IBS-C were diagnosed based on the Rome III criteria. Randomized subjects were administered 30 mg of DA-9701 or placebo 3 times a day for 4 weeks. The study endpoints were evaluated the percentage of responders in the overall symptom evaluation of IBS-C and FD.

Results:
Thirty IBS-C patients and 30 placebos were prospectively enrolled. The proportion of responders with improvement in overall symptoms of IBS-C was 53.33% in the DA-9701 group and 40.00% in the placebo group (P = 0.301). Compared to the placebo group, the decrease of abdominal pain score in the DA-9701 group was significantly higher at week 3 in the DA-9701 group (0.96 ± 0.77 vs 0.55 ± 0.79, P = 0.042) but no significance at week 4. There was no significant difference in total IBS quality of life score at week 4 between the 2 groups (P = 0.897). Among patients with IBS-C accompanied by FD, the proportion of responders in the DA- 9701 group was 50.00% (15/30), which was higher than 31.03% (9/29) of the placebo group (P = 0.138).

Conclusions:
DA-9701 showed trend of treatment efficacy in patients with IBS-C and FD overlap including overall improvement, and safety, compared to placebo but without significance probably due to small numbers. It is suggested the need for a large-scale clinical trial to confirm this preliminary effect of DA-9701.
Keimyung Author(s)(Kor)
이주엽
Publisher
School of Medicine (의과대학)
Citation
Ju Yup Lee et al. (2022). A Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of DA-9701 (Motilitone) in Patients With Constipation-type Irritable Bowel Syndrome and Functional Dyspepsia Overlap: A Pilot Study. J Neurogastroenterol Motil, 28(2), 265–275. doi: 10.5056/jnm20236
Type
Article
ISSN
2093-0887
Source
https://www.jnmjournal.org/journal/view.html?uid=1748&vmd=Full&
DOI
10.5056/jnm20236
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/44228
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.